Pacira BioSciences, Inc. (PCRX) Comparison with companies in other sectors?

Pacira BioSciences, Inc. has a share price of 46.30M. You can analyze Pacira BioSciences, Inc. (PCRX) competitors across different market sectors through stock heatmaps.

What are PCRX's NET and operating margins?

Pacira BioSciences, Inc. (PCRX) operating margin is around -0.12, and net profit margin is approximately -0.15 as of the latest reports.

In what way does PCRX's earnings per share (EPS) trend reflect its financial momentum?

Pacira BioSciences, Inc. (PCRX) EPS is -2.24 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Pacira BioSciences, Inc. is -10.07, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Pacira BioSciences, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Pacira BioSciences, Inc. like P/E which is -9.99, P/B which is 1.30, and PEG which is 2.40. Compare them with sector averages to evaluate if the stock is priced fairly.

Pacira BioSciences, Inc.

PCRX•NASDAQ

Healthcare

Drug Manufacturers - Specialty & Generic

$22.55

$0.73(3.35%)

Fundamental Analysis of Pacira BioSciences, Inc. (PCRX)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-2.24

P/E Ratio

-10.07

ROE

-0.13%

Net Margin

-0.15%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$1.04B

Shares OutstandingTotal number of shares issued

$46.30M

Book Value/ShareNet worth per share

$17.26

Revenue/ShareAnnual revenue per share

$15.19

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-2.24

Net MarginNet income as percentage of revenue

-14.76%

Operating MarginOperating income as percentage of revenue

-11.65%

ROEReturn on shareholders' equity

-12.94%

ROAReturn on total assets

-6.54%

ROCEReturn on capital employed

-6.44%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$3.44

Cash/ShareCash and equivalents per share

$10.67

FCF YieldFree cash flow as percentage of market cap

15.45%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for PCRXFinancial Ratios Analysis details for PCRX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for PCRXSector Benchmarking details for PCRX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Pacira BioSciences, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Pacira BioSciences, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Pacira BioSciences, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Pacira BioSciences, Inc.

For Pacira BioSciences, Inc., essential financial indicators include EPS -2.24, PE -10.07, and ROE -0.13. These key ratios reveal insights into Pacira BioSciences, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Pacira BioSciences, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Pacira BioSciences, Inc.

Metrics like Net Margin -14.76% and ROA -6.54% shed light on how well Pacira BioSciences, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Pacira BioSciences, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Pacira BioSciences, Inc.

Using ratios such as P/B Ratio 1.30 and PEG Ratio 2.40, investors can assess whether Pacira BioSciences, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Pacira BioSciences, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Pacira BioSciences, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.80 and Cash Flow $3.44, provide a snapshot of Pacira BioSciences, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Pacira BioSciences, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Pacira BioSciences, Inc.

Investing in Pacira BioSciences, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Pacira BioSciences, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;